Del Carmen Jeffrey
Chief Commercial Officer
Del Carmen Jeffrey has filed 5 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Jul 17, 2026.
On the most recent filing, Del Carmen Jeffrey is listed as Chief Commercial Officer at CATALYST PHARMACEUTICALS, INC. Inside the rolling window, Del Carmen Jeffrey reported no open-market purchases and 1 open-market sale totaling $256K in CPRX.
Companies traded
Other insiders at CPRX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$256K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Del Carmen Jeffrey made?
Del Carmen Jeffrey has filed 5 SEC Form 4 filings (9 transaction rows) across 1 company since 2025.
Which companies does Del Carmen Jeffrey trade?
Del Carmen Jeffrey has filed SEC Form 4 disclosures for 1 company, including CPRX.
When was Del Carmen Jeffrey's most recent SEC Form 4 filing?
Del Carmen Jeffrey's most recent SEC Form 4 filing on Tracefour is dated Jul 17, 2026.
What is Del Carmen Jeffrey's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Del Carmen Jeffrey is listed as Chief Commercial Officer.
What is Del Carmen Jeffrey's total buy and sell value in the current window?
Inside the rolling retention window, Del Carmen Jeffrey bought $0 and sold $256K based on SEC Form 4 filings.
What was Del Carmen Jeffrey's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,983 CPRX shares on 2025-11-26, worth $256K, per SEC Form 4 filings.